翰森制药(03692)自主研发1类新药HS-10582片获NMPA临床试验批准

公告速递
Aug 06

2026年8月6日,翰森制药集团有限公司(03692)公告称,其自主研发的1类新药HS-10582片已获中国国家药品监督管理局签发的《药物临床试验批准通知书》,拟用于开展治疗成人原发性高胆固醇血症和混合型血脂异常的临床试验。

公告显示,HS-10582片由翰森制药自主研发,获批后将进入临床阶段研究,为公司在心血管代谢领域的管线布局再添新进展。

董事会表示,相关临床试验启动后将按照监管要求推进,并于适时披露项目进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10